1-(2,4-DICHLOROPHENYL)-4-OXOCYCLOHEXANECARBONITRILE, 95.0%, 1g

(R)-2-Amino-2-methyl-3-phenylpropanoic acid, 95.0%, 5g

Dimethyl 5-methylisophthalate, 95.0%, 5g

1-(2-Bromo-6-hydroxyphenyl)ethanone, 95.0%, 5g

4-Amino-3-fluorophenol>98.0%(GC)(T)5g

Di-tert-butyl 1,4-Dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate>98.0%(HPLC)(T)1g

2,6-Bis(trifluoromethyl)aniline, 95.0%, 1g

Methyl 4-(Cyanomethyl)benzoate>95.0%(GC)5g

Ethyl 4-ethyl-3-methyl-1H-pyrrole-2-carboxylate, 97%, 2g

N-Boc-4-Acetylpiperidine, 98.0%, 25g

Methyl 2-chloro-4-(methylsulfonamido)benzoate, 97.0%, 5g

iScope IS.1158-PLPHi Biocular for phase contrast with Plan phase IOS objectives and Rackless cross stage (infinity - ergonomic tilting head)